Mr. Evans joined ARCH Venture Partners in 2017 as a Venture Partner. He brings significant experience as a company builder, deal maker, and drug developer in the pharmaceutical and biotechnology fields.
Prior to ARCH, Mr. Evans was an early employee and leadership team member at Agios Pharmaceuticals (AGIO), most recently serving as SVP Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA (AG-221) and AG-120. He helped initiate and lead Agios’s landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple innovative research collaborations in cancer metabolism. He also initiated and co-led Agios’s strategic expansion into rare genetic metabolic diseases. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals as program executive for the company’s Hsp90 inhibitors. He has also worked at McKinsey & Company (Pharmaceuticals practice), MedImmune, and Bayer Pharmaceuticals.
Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, an M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.